PanTher’s skilled management team offers years of experience in oncology, biomedical devices, business, and entrepreneurship.
Laura Indolfi
Chief Executive Officer, Co-Founder
Dr. Indolfi combines the science and business knowledge to drive our vision. As a biomedical engineer, Laura has 10 years of local drug delivery experience. Her expertise covers a broad range of therapeutic areas (cancer, inflammation, regenerative medicine) and approaches (drug delivery, cell therapy, implanted devices).
She has also developed hands-on business managerial know-hows through classes at the Sloan School of Management and Harvard Business School.
Laura holds a PhD in Biomaterials from the University “Federico II” of Naples in Italy and completed post-doc training at MIT and MGH Cancer Center.
David Ting
Scientific Co-Founder
Dr. Ting is a translational pancreatic cancer researcher and practicing board certified oncologist at the Massachusetts General Hospital (MGH) Cancer Center. He obtained BS degrees in both biology and chemical engineering from MIT and completed his MD at Harvard Medical School. He performed biomedical research under Dr. Robert Langer working on DNA vaccine delivery systems and then a Howard Hughes Medical Fellowship with Dr. George Daley on stem cell research.
David is now an Assistant Professor at the MGH Cancer Center and Harvard Medical School directing a translational research laboratory focused on pancreatic cancer.
Elazer Edelman
Scientific Co-Founder
Key Opinion Leader in local drug delivery and implantable devices, Dr. Edelman serves as an advisor for the FDA and several companies in the medical device industry, and has been instrumental in propelling a number of critical devices from conceptualization to clinical realization.
Elazer is a Professor of Health Sciences and Technology at MIT and Professor of Medicine at Harvard Medical School. He also directs the Harvard-MIT Biomedical Engineering Center (BMEC), dedicated to applying the rigors of the physical sciences to elucidate fundamental biologic processes and mechanisms of disease.
Meg Lashof-Sullivan
Scientist
Dr. Lashof-Sullivan is a biomedical engineer with a background in biomaterials. She has expertise in polymer synthesis, drug delivery, and analytical laboratory techniques.
Meg received her B.E. degree from the Thayer School of Engineering at Dartmouth College, and her PhD in Biomedical Engineering from Case Western Reserve University.
She completed postdoctoral training at the Naval Medical Research Center’s NeuroTrauma department.
Baruch Harris
VP Business Operations
Dr. Harris is a biotechnology executive with nearly 15 years experience across diverse business functions in small and large biopharma companies. In his most recent full-time role Baruch was Senior Director, Corporate Development and Program Executive at FORUM Pharmaceuticals.
Before FORUM, he was a Venture Partner at Fidelity Biosciences (now F-Prime Capital Partners); Chief Business Officer at Enlight Biosciences (PureTech Ventures); Executive Director & Head of Business Strategy and Operations for Novartis Biologics. He received his Ph.D. in Biochemistry & Molecular Biology from the University of California, San Francisco, and his Sc.B. in Biophysics from Brown University.